Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Un écran d'ordinateur avec une image médicale

Bidding Program Big Brain Theory

Exploring new avenues

Last update: 17/01/2025 Reading time: 1min

Launched in June 2015 by Paris Brain Institute, the Big Brain Theory (BBT) programme funds innovative, interdisciplinary, high-risk projects co-sponsored by various in-house research teams.

Origins of the programme

Origins of the programme

The Big Brain Theory program was born out of an original idea: what if it were possible to do research differently, more boldly and interdisciplinarily, to find tomorrow’s treatments for brain diseases?

Why "Big Brain"? Because the challenges of the brain are immense, and because so are our ambitions to serve patients.

Why “Theory”? Because we want to propose unexplored ideas and new ways to advance our understanding of our brain.

This research program now includes many bold and innovative projects, some of which have already led to major discoveries.

Exploring new avenues

Exploring new avenues

Since its inception, the Big Brain Theory program has provided grants for innovative, interdisciplinary new projects in neuroscience for researchers and clinicians at the Institute.

Paris Brain Institute hopes that each "Big Brain Theory" will aim to engage each Principal Investigator and Platforms in a collaborative effort to broaden the impact of individual-level research and develop new pioneering projects that translate into collective advances that will become the symbols of the Institute.

News that might interest you

À la recherche de marqueurs d’imagerie dans la démence frontotemporale
Searching for Imaging Markers in Frontotemporal Dementia
Could exploring the relationships between different brain networks help us understand frontotemporal dementia (FTD)? This neurodegenerative disease, which progresses at varying rates, is often diagnosed late—when clinical signs are already severe. At...
01.07.2025 Research, science & health
Monocyte – un globule blanc qui se différencie en macrophage. Crédit : Université d’Edinbourg.
Discovery of a Macrophage Anomaly in Multiple Sclerosis
Certain patients with multiple sclerosis (MS) can partially regenerate myelin—the protective sheath that surrounds nerve fibers—which is damaged during the evolution of the disease. In studying how immune cells influence this remyelination...
12.19.2024 Research, science & health
Interneurones. Crédit : UCLA Broad Stem Cell Research Center.
Stimulating specific neurons in the striatum stops compulsive behaviour
What if we could resist compulsions? These irrational behaviours, particularly common in obsessive-compulsive disorder (OCD), are hard to suppress. At Paris Brain Institute, Éric Burguière's team shows that we can anticipate them and block them...
09.10.2024 Research, science & health
Les nerfs moteurs présents dans la moelle épinière se projettent vers la périphérie, où ils entrent en contact avec les muscles, formant des connexions appelées jonctions neuromusculaires. Crédit : James N. Sleigh.
Ultrasound show unexpected effects on motor neuron disease
Over the past fifteen years, neurosurgeons have been perfecting a fascinating technique: using ultrasound to temporarily open the blood-brain barrier to facilitate the action of therapeutic molecules in the central nervous system. At Paris Brain...
09.05.2024 Research, science & health
Un neurone
Rett syndrome: a new gene therapy on the way
Gene therapy could be our best chance of treating Rett syndrome, a neurological disorder that causes severe intellectual and motor impairments. At Paris Brain Institute, Françoise Piguet and her colleagues have looked closely at brain cholesterol...
07.16.2024 Research, science & health
Lésions d’un patient à l’inclusion dans le protocole (M0) disparues après 2 ans de traitement à la Leriglitazone (M24)
The dual effect of leriglitazone in X-linked Adrenoleukodystrophy (X-ALD)
In 2023, the team led by Professor Fanny Mochel (AP-HP, Sorbonne University), a Paris brain Institute researcher, showed that daily dose of leriglitazone slow down the progression of myelopathy in patients with X-linked adrenoleukodystrophy, and...
06.28.2024 Research, science & health
See all our news